The authors demonstrated that CD8+ T-cell differentiation is regulated through the miR-155–Phf19 (PHD Finger Protein 19)–PRC2 (polycomb repressive complex 2) axis, paving the way for new methods for potentiating cancer immunotherapy through epigenetic reprogramming of CD8+ T-cell fate [79]. Here, CD8A is linked to cancer.